key: cord-0982949-0kpussg7
authors: Mei, Jie; Zhou, Yatong; Yang, Xinping; Zhang, Fan; Liu, Xiufeng; Yu, Boyang
title: Active components in Ephedra sinica Stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: potent COVID-19 therapeutic agents
date: 2021-06-05
journal: J Ethnopharmacol
DOI: 10.1016/j.jep.2021.114303
sha: 4bfd890acb524664f1e1377c10fb4761d4a5b9c1
doc_id: 982949
cord_uid: 0kpussg7

ETHNOPHARMACOLOGICAL RELEVANCE: Ephedra sinica Stapf is a widely used folk medicine in Asia to treat lung diseases, such as cold, cough and asthma. Many efforts have revealed that some traditional Chinese medicine (TCM) prescriptions containing Ephedra sinica could effectively alleviate the symptoms and prevent the fatal deterioration of COVID-19. Aim of the study: The present study aims to discover active compounds in Ephedra sinica disrupting the interaction between angiotensin-converting enzyme 2 (ACE2) and the SARS-CoV-2 spike protein receptor-binding domain (SARS-CoV-2 RBD) to inhibit SARS-CoV-2 virus infection. MATERIALS AND METHODS: The ethanol extracts of Ephedra sinica were prepared. Activity guided isolation of constituents was carried out by measuring the inhibitory activity on ACE2-RBD interaction. The structures of active compounds were identified by HPLC-Q-TOF-MS/MS and NMR. To testify the contribution of main components for the inhibitory activity, different samples were prepared by components knock-out strategy. The mechanism of compounds inhibiting protein-protein interaction (PPI) was explored by competition inhibition assays, surface plasmon resonance (SPR) assays and molecular docking. SARS-CoV-2 S protein-pseudoviruses were used to observe the viropexis effect in cells. RESULTS: Ephedra sinica extracts (ESE) could effectively inhibit the interaction between ACE2 and SARS-CoV-2 RBD (IC(50) = 95.01 μg/mL). Three active compounds, 4,6-dihydroxyquinoline-2-carboxylic acid, 4-hydroxyquinoline-2-carboxylic acid and 4-hydroxy-6-methoxyquinoline-2-carboxylic acid were identified to inhibit ACE2-RBD interaction (IC(50) = 0.58 μM, 0.07 μM and 0.15 μM respectively). And knock-out the three components could eliminate the inhibitory activity of ESE. Molecular docking calculations indicated that the hydrogen bond was the major intermolecular force. Finally, our results also showed that these compounds could inhibit the infectivity of SARS-CoV-2 S protein-pseudoviruses to 293T-ACE2 (IC(50) = 0.44 - 1.09 μM) and Calu-3 cells. CONCLUSION: These findings suggested that quinoline-2-carboxylic acids in Ephedra sinica could be considered as potential therapeutic agents for COVID-19. Further, this study provided some justification for the ethnomedicinal use of Ephedra sinica for COVID-19.

Results: Ephedra sinica extracts (ESE) could effectively inhibit the interaction between ACE2 and 45 SARS-CoV-2 RBD (IC 50 = 95.01 μg/mL). Three active compounds, 46 4,6-dihydroxyquinoline-2-carboxylic acid, 4-hydroxyquinoline-2-carboxylic acid and 47 4-hydroxy-6-methoxyquinoline-2-carboxylic acid were identified to inhibit ACE2-RBD interaction 48 (IC 50 = 0.58 µM, 0.07 µM and 0.15 µM respectively). And knock-out the three components could 49 eliminate the inhibitory activity of ESE. Molecular docking calculations indicated that the hydrogen 50 bond was the major intermolecular force. Finally, our results also showed that these compounds 51 could inhibit the infectivity of SARS-CoV-2 S protein-pseudoviruses to 293T-ACE2 (IC 50 = 0.44 -52

Conclusion: These findings suggested that quinoline-2-carboxylic acids in Ephedra sinica could be 54 considered as potential therapeutic agents for COVID-19. Further, this study provided some 55 justification for the ethnomedicinal use of Ephedra sinica for COVID-19. The raw data were analyzed using GraphPad Prism 6.0 software. All data are presented as 213 mean ± SEM (standard error of the mean) of six independent assays. A value of P<0.05 was 214 considered statistically significant. 215 In order to measure the inhibitory activity on ACE2-RBD interaction, a biotinylated binding 220 assay was established to evaluate the binding efficacy of ACE2 and RBD. The principle of the assay 221 was shown as Fig. 1A . The binding amount of the biotin-labeled ACE2 to the RBD coated on the 222 96-well plate could be detected directly by the color change of the TMB solution. Similarly, the 223 binding amount of the biotin-labeled RBD to the ACE2 coated on a 96-well plate could also be 224 tested by this method. To make sure the protein was active, the binding kinetics of ACE2 and 

RBD from Ephedra sinica 249 ESE was evaluated for its inhibitory efficacy on ACE2-RBD interaction. The relative 250 inhibition ratio was determined by the biotinylated binding assay. As shown in Fig. 2A , ESE could 251 block the interaction between ACE2 and RBD with an IC 50 of 95.01 μg/mL. Then, we focused on 252 finding biologically active molecules in ESE by activity guided isolation which has been proven to 253 be an effective method to find biologically active molecules in natural products. Here, we 254 performed HPLC to gradually separate the compounds in the ESE and tracked the biologically 255 active ingredients persistently. As shown in Fig. 2B , an HPLC chromatogram of the ESE at a 256 monitoring wavelength of 254 nm was established to identify as many compounds as possible. According to the retention time in the chromatogram, the ESE fraction 1 is subdivided into eleven 281 sub-fractions, and the relative inhibition rate is determined by the biotinylated binding assay 282 experiment. Data are shown as mean ± SEM of six independent assays. *P<0.05, **P<0.01, 283 ***P<0.001, ****P<0.0001 compared with solvent. 284

Components knock-out technology is a good method to identify the active ingredients in 288 natural products (Liu, X et al., 2020). Here, we prepared compounds 1-3 knock-out samples (ESE 289 without compounds 1-3), components knock-in samples (compounds 1-3 were added to the 290 knock-out sample) and their HPLC chromatograms were shown in Fig. 3B . These fractions were 291 tested in the binding assay for their inhibitory potential on ACE2-RBD interaction. As shown in Fig.  292 3C, compounds 1-3 blocked the interaction between ACE2 and RBD. However, the ability of 293 knock-out sample to block the interaction between ACE2 and RBD was lost. Interestingly, this 294 ability was restored to an equivalent level to ESE after knocking in compounds 1-3, indicating that 295 compounds1-3 may be the main active ingredients in ESE on blocking the interaction between 296 ACE2 and RBD. In order to evaluate the activity of disrupting ACE2-RBD interaction of different 297 compounds, we optimize the concentration of biotinylated ACE2 as described previously (Walker et 298 al., 2020) . The biotinylated ACE2 at the concentration of 0.06 μg /mL showed a complete inhibition 299 curve and appropriate response value (OD450) in the presence of soluble recombinant human ACE2 300 ( Supplementary Fig. 5 ). As shown in Fig. 3D -F, on this optimal condition, compounds 1-3 blocked 301 the interaction between SARS-CoV-2 RBD and ACE2 in a dose-dependent manner with IC 50 of 302 0.58 μM, 0.07 μM and 0.15 μM with a complete blocking curve. There is no significant difference 303 in the inhibitory activity of these three compounds. 304 

To investigate the principle of the inhibitory efficacy on ACE2-RBD interaction, we further 315 addressed the binding of compounds 1-3 with SARS-CoV-2 RBD or ACE2. As shown in Fig. 4A , 316 three parallel experiments were conducted. (I) 10 μM three Compounds (Cpds) were incubated with 317 relative amount of biotinylated ACE2 was determined; (Ⅱ) 10 μM Cpds were incubated with 319 immobilized ACE2 respectively and washed to remove the unbound part, then the relative amount 320 of biotinylated SARS-CoV-2 RBD was determined; (Ⅲ) Biotinylated ACE2 was incubated with 321 immobilized SARS-CoV-2 RBD and washed to remove the unbound part, then 10 μM Cpds were 322 added respectively. Finally, relative amount of biotinylated ACE2 was determined. As shown in Fig.  323 4B, when compounds 1-3 were incubated with immobilized SARS-CoV-2 RBD, all the relative 324 amounts of bound ACE2 were significantly reduced compared with the solvent control group 325 (P<0.05). Correspondingly, when compounds were incubated with immobilized ACE2, the amounts 326 of bound SARS-CoV-2 RBD did not change significantly compared with the solvent control group. 327

These results indicated that the three compounds inhibited PPI by binding to SARS-CoV-2 RBD 328 instead of ACE2. In addition, after adding compounds 1-3 into combined ACE2 and RBD (Fig. 4A  329   Ⅲ ), all the relative amounts of bound ACE2 were significantly reduced compared with the solvent 330 control group (P<0.05), indicating that the three compounds could also promote the dissociation of 331 ACE2 and RBD. 332

To further verify the above results, the direct binding between the compounds and proteins 333 were analyzed by SPR assay. Compound 2 bound to immobilized SARS-CoV-2 RBD in a 334 dose-dependent manner. The K D value of compound 2 is 5.28 μM (Fig. 4C) . While, compound 2 335 displayed low or no binding with ACE2 (Fig. 4D) . Similarly, as shown in Fig. 4E and 4F, the 336 interactions between the other two compounds and the SARS-CoV-2 RBD were concentration 337 dependent. The K D value of compound 1 was 0.60 μM and compound 3 was 5.37 μM. To evaluate 338 2, the mixture was injected over ACE2 immobilized on the biosensor chip. As shown in Fig. 4G , the 341 binding of SARS-CoV-2 RBD to ACE2 was blocked by compound 2 in a dose-dependent manner. 342

These findings suggested that compound 1-3 could block the ACE2-RBD interaction by directly 343 binding to SARS-CoV-2 RBD at the binding interface. with SARS-CoV-2 RBD (Fig. 5E) . It was worth noting that Tyr449 and Gln498 were the key ACE2 381 binding residues that have been previously identified (Yi et al., 2020) . The combination of 382 compounds 1-3 with these key amino acid residues may be the reason for its inhibitory activity on 383 the interaction between ACE2 and RBD. 384 of compounds 1-3 in vitro. We first examined the cell toxicity to 293T-ACE2 cells of the 395 compounds 1-3 and soluble human ACE2. As shown in Fig. 6A Calu-3 cells were infected with S protein-pseudoviruses in the presence or absence of ESE, 407 compound 2 or soluble human ACE2 respectively. As shown in Supplementary Fig. 1, ESE and  408 compound 2 also abolished the infectivity of SARS-CoV-2 S protein-pseudoviruses to Calu-3 cells. 409

These findings indicated that quinoline-2-carboxylic acids were novel compounds that were able to 410 reduce the infectivity of SARS-CoV-2 S protein-pseudoviruses to 293T-ACE2 and Calu-3 cells. 411 

TCMs as great resource of bioactive natural products are widely used to treat COVID-19 (Xian 421 et al., 2020) . However, the active ingredients and molecular mechanisms still need to be clarified. In 422 the present study, we confirm for the first time that quinoline-2-carboxylic acids in Ephedra sinica 423 can disrupt ACE2-RBD interaction and inhibit the entry of pseudoviruses. 424

We initially performed biotinylated binding assay to determine whether ingredients from 425

TCMs could disrupt ACE2-RBD interaction (Fig. 1A) . We found that the ESE displays significant 426 inhibitory activity ( Fig. 2A) . We initially used activity guided isolation and components knock-out 427 technology to identify inhibitors of ACE2-RBD interaction from ESE (Fig. 2D, 3C) . In this study, 428 we demonstrated that 4,6-dihydroxyquinoline-2-carboxylic acid, 4-hydroxyquinoline-2-carboxylic 429 acid and 4-hydroxy-6-methoxyquinoline-2-carboxylic acid were main active components in 430

Ephedra sinica blocking ACE2-RBD interaction (Fig. 3D-F) . However, the relative inhibition ratio 431 of the mix of compounds 1-3 was lower than ESE (Fig. 3C) , that means there are other components 432 disrupting the interaction. That is consistent with the literature (Lv et al., 2021) . 433

It is worth noting that ESE and the active ingredients not only prevent the ACE2-RBD 434 interaction, but also promote the dissociation of the S protein that has bound the receptor (Fig. 4A Ⅲ , 435 B). It means that quinoline-2-carboxylic acids are possible to play crucial roles in the treatment and 436 prevention of viruses' invasion at the same time. Interestingly, 4-hydroxyquinoline-2-carboxylic 437 acid (kynurenic acid) is one of the metabolites in human, the latest research showed that the content 438 of kynurenic acid in serum of patients with COVID-19 was higher than that in negative controlled 439 ACE2-RBD interaction, which may be related to self-antiviral mechanism. 441 Traditionally, ephedrine and pseudoephedrine were considered to be the main active 442 ingredients in Ephedra sinica but the serious side effects of these compounds restricted the clinical 443 use of ephedra (Anderson, 2018; Wei et al., 2019). Here we proved that three trace components in 444

Ephedra sinica not only inhibited the PPI between ACE2 and RBD but also effectively blocked the 445 invasion of pseudovirus in vitro. We put forward a new point of view for the rational use of 446

Ephedra sinica and also prove that activity guided isolation is a good strategy for the discovery of 447 bioactive microconstituents in natural products. 448

We further demonstrated that quinoline-2-carboxylic acids inhibited PPI by directly binding to 449 SARS-CoV-2 RBD instead of ACE2 (Fig. 4C, D) . Based on the molecular docking and SPR assay, 450 we speculated that these compounds might bind to interface between ACE2 and RBD that 451 contributes to the disruption of the PPI. The structure of quinoline-2-carboxylic acid is important 452 for the study on the inhibitory activity. The amidogen and carboxyl groups have two strong 453 hydrogen interactions with Gln 498 (Fig. 5) . These interactions might verify that 454 quinoline-2-carboxylic acids have potent inhibitory activity against SARS-CoV-2. 455

The entry of virus into the cells is a critical step in the process of virus infection. However, 456 SARS-CoV-2 related researches were greatly limited by the regulation that the safety level of the 457 laboratory for direct research using virus strains need to achieve 3 or higher. The study on 458 pseudoviruses made the conduct of researches safer and much more efficient. The surface of the 459 pseudoviruses expresses the SARS-CoV-2 Spike protein and the viruses carry both the GFP and 460 cells can be evaluated by observing the fluorescence signal and detecting the luciferase activity. We 462 confirm that quinoline-2-carboxylic acids have the ability to suppress the entrance of SARS-CoV-2 463 S protein-pseudoviruses into 293T-ACE2 and Calu-3 cells (Fig 6, Supplementary Fig. 1) 

Discovery of SARS-CoV-2 antiviral drugs through 590 large-scale compound repurposing

Photophysical aspects of biological photosensitizer 592

Kynurenic acid from the perspective of experimental and quantum chemical study

Cell entry mechanisms of SARS-CoV-2

Quinoline-2-carboxylic acids from Ephedra species

COVID-19 infection alters kynurenine and fatty 600 acid metabolism, correlating with IL-6 levels and renal status

SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition 605 in vaccinated animals and infected patients

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Clinical Characteristics of 138 Hospitalized Patients With

Coronavirus-Infected Pneumonia in Wuhan

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Ma Huang Tang and Investigation on the Ephedra Alkaloids Efficacy on Influenza Virus Type A

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Nowcasting and forecasting the potential domestic and international 624 spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

Bioactive natural compounds against 633 human coronaviruses: a review and perspective

Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in 638 treatment of COVID-19: A randomized controlled trial

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact

The authors declare that they have no conflict of interest. 514